Re-Engineering Basic and Clinical Research to Catalyze Translational Nanoscience

重新设计基础和临床研究以促进转化纳米科学

• 批准号: 0805207
• 负责人: James Murday
• 金额: $ 1万
• 依托单位: University of Southern California
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0805207&HistoricalAwards=false
• 关键词: Re; Engineering; Basic; Clinical; Research

The specific objectives are to:-Establish priorities for future translational nanomedicine and stimulate research, whereby nanotechnologies and nanoscience paradigms will facilitate drug delivery, drug and therapeutic development, in vivo imaging, in vitro diagnostics, active implants and tissue repair/regeneration.-Include as speakers a multidisciplinary group of outstanding scientists and engineers from academia and industry working in the materials, biological and physical science disciplines toward the development of nanodevices and nanotechnologies, together with visionary clinicalresearchers from translational research programs supported by NIH and the Howard Hughes Medical Institute who have expertise in genomics, proteomics, multiple organ systems, molecules and pathways implicated in common human diseases.- Stimulate uniquely transformative, novel, and integrative strategies to catalyze the application to clinical practice of. This includes acceleration of the development of nanoscale techniques that enable in vivo probes of cellular and subcellular physiology.

具体目标是：-为未来的翻译纳米医学建立优先事项并刺激研究，从而纳米技术和纳米科学范式将促进药物递送，药物和治疗开发，体内成像，体外诊断，活性植入物和组织修复/再生。包括作为发言人的一个多学科小组的杰出科学家和工程师从学术界和工业界的工作在材料，生物和物理科学学科对纳米器件和纳米技术的发展，以及有远见的临床研究人员从翻译研究计划支持的NIH和霍华德休斯医学研究所谁拥有基因组学，蛋白质组学，多器官系统，与人类常见疾病有关的分子和途径。刺激独特的变革性，新颖性和综合性策略，以促进临床实践的应用。这包括加速纳米技术的发展，使体内探针的细胞和亚细胞生理学。